Amyris Inc (NASDAQ:AMRS) was the target of unusually large options trading on Wednesday. Stock traders acquired 813 call options on the stock. This is an increase of 1,406% compared to the average daily volume of 54 call options.

A number of hedge funds and other institutional investors have recently made changes to their positions in AMRS. Bank of New York Mellon Corp raised its holdings in Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 4,603 shares in the last quarter. Carl Domino Inc acquired a new position in Amyris in the 3rd quarter valued at $182,000. KBC Group NV raised its holdings in Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 41,834 shares in the last quarter. Finally, Tanaka Capital Management Inc. raised its holdings in Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after acquiring an additional 221,295 shares in the last quarter. 22.84% of the stock is owned by hedge funds and other institutional investors.

Amyris (NASDAQ:AMRS) opened at $4.64 on Friday. The firm has a market capitalization of $199.68, a price-to-earnings ratio of -0.75 and a beta of 0.16. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78. Amyris has a fifty-two week low of $1.86 and a fifty-two week high of $12.28.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.04). The business had revenue of $24.20 million during the quarter, compared to analysts’ expectations of $36.30 million. Amyris’s quarterly revenue was down 8.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.07) earnings per share. equities research analysts anticipate that Amyris will post -3.32 earnings per share for the current fiscal year.

Several research firms recently weighed in on AMRS. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Amyris in a report on Tuesday, September 26th. Cowen reissued a “hold” rating and set a $4.00 price target on shares of Amyris in a report on Wednesday, November 29th. Zacks Investment Research raised Amyris from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Wednesday, October 4th. Finally, ValuEngine cut Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/13/amyris-target-of-unusually-large-options-trading-amrs.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.